HC Wainwright & Co. Reiterates Buy on Immunic, Maintains $22 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 88.3%

Neg 0% Neu 88.3% Pos 0%

HC Wainwright & Co. analyst Matthew Caufield reiterates Immunic (NASDAQ:IMUX) with a Buy and maintains $22 price target.